Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...

Thursday, Bayer shared top-line data from a phase 3 trial that tested elinzanetant in women on adjuvant endocrine therapy for ...

Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) announced Thursday that elinzanetant, its experimental therapy for hot flashes, reached the ...

As Bayer awaits an FDA decision on its non-hormonal treatment for hot flashes caused by menopause, it's unveiling new results ...

As US Surgeon General Dr. Vivek Murthy nears the end of his second term as the nation’s doctor, a final diagnosis of his ...

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of ...

3 effective hot flash treatments Even though you can't prevent vasomotor symptoms like hot flashes, there are easy ways to manage them. "Women need to consider a menu of options, and that's where ...

Vasomotor symptoms are a common problem in women with HR-positive breast cancer receiving anti-cancer therapy.

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

At the time, it was the first non-hormonal prescription option for treating hot flashes. The medication ... during the first three months of Veozah treatment and follow-up tests at months six ...

Veozah is an oral, neurokinin 3 receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. The labeling for the product now includes a boxed warning ...

Hepatic function should be evaluated prior to initiating treatment with Veozah. The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk ...